FunPlus Senior Leadership Team Welcomes Eleanor Twilton Ben Youssef as Global Head of PR & Comms
18.8.2021 18:04:00 EEST | Business Wire | Press release
Today, FunPlus, a leading independent mobile game developer and publisher, announced that Eleanor Twilton Ben Youssef has been appointed as Global Head of PR & Comms for the Switzerland-based company. Reporting to Chief Business Officer Chris Petrovic, Twilton will be responsible for implementing FunPlus’ global external and internal communications strategies, including public relations, corporate and employer brand communications, events, and CSR initiatives.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005560/en/
FunPlus Senior Leadership Team Welcomes Eleanor Twilton Ben Youssef as Global Head of PR & Comms (Photo: Business Wire)
“Eleanor’s expertise and industry know-how are exactly what we’ve been looking for as FunPlus moves to the forefront of conversations about industry leaders,” said Petrovic. “As we look to grow our games and amplify the impact they already have, we couldn’t be in better hands.”
“I am thrilled to be joining FunPlus and its growing team of senior leaders,” said Twilton. “I have been inspired and impressed by FunPlus’ culture, ambition, and its talented teams and engaged communities. I am looking forward to supporting the company’s vision and continuing efforts to become not only the best among gaming companies, but the best in the broader interactive entertainment space.”
With more than a decade of experience managing comms for Ubisoft, one of the biggest game developer/publishers in the world, Twilton will enhance FunPlus’ publicity efforts as the company continues to produce and elevate hugely successful games like State of Survival and King of Avalon while providing a work experience that attracts talent from the extremely competitive games and tech industry.
For more information on FunPlus, visit http://www.FunPlus.com. Find a link to assets here.
About FunPlus
Founded in 2010, FunPlus is a world class, independent game developer and publisher headquartered in Switzerland with operations in Spain, Sweden, Russia, United States, Singapore, Japan, and China. As an organization that fosters the best creative talent in the world and employs nearly 2,000 people, the company has developed and published mobile games that have ranked in the #1 spot in nearly 70 countries, which includes State of Survival, King of Avalon, and Guns of Glory. FunPlus studios include KingsGroup, Puzala, Seven Games, and Imagendary Studios, each part of a growing global network of developers working on unique brands of staple genres including strategy, puzzle, and role-playing games.
As the top publisher in the 4X strategy category for 3 years in a row, FunPlus has leveraged this success to bring the worlds of gaming and mainstream entertainment together through successful collaborations with top tier IP such as AMC’s The Walking Dead, which is currently live in the company’s biggest game, State of Survival.
The FunPlus brand powers FunPlus Phoenix (FPX), one of the world’s most successful esports organizations.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210818005560/en/
Contact information
BHI/42West for FunPlus
Jamie King
Jamie_King@bhimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 10:00:00 EEST | Press release
Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defies convention and empowers individuals to express their identity and bring out confidence. At the heart of this vision is the brand’s signature shadow enhancing makeup approach
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom